메뉴 건너뛰기




Volumn 36, Issue 8, 2016, Pages 1647-1650

Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia - Brief Report

(19)  Thedrez, Aurélie a   Sjouke, Barbara b   Passard, Maxime a   Prampart Fauvet, Simon a   Guédon, Alexis a   Croyal, Mikael a   Dallinga Thie, Geesje b   Peter, Jorge b   Blom, Dirk c   Ciccarese, Milco d   Cefalù, Angelo B e   Pisciotta, Livia f   Santos, Raul D g   Averna, Maurizio e   Raal, Frederick h   Pintus, Paolo h   Cossu, Maria d   Hovingh, Kees b,i   Lambert, Gilles a,j,k,l  


Author keywords

alirocumab; hypercholesterolemia; proprotein convertase subtilisin kexin type 9; receptors, LDL; therapeutics

Indexed keywords

ALIROCUMAB; COMPACTIN; ENZYME INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; UNCLASSIFIED DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LDLR PROTEIN, HUMAN; LDLRAP1 PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE INHIBITOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

EID: 84963576832     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.307493     Document Type: Article
Times cited : (20)

References (15)
  • 1
    • 84918820589 scopus 로고    scopus 로고
    • PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels
    • Marais AD, Kim JB, Wasserman SM, Lambert G. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. Pharmacol Ther. 2015;145:58-66. doi: 10. 1016/j. pharmthera. 2014. 07. 004
    • (2015) Pharmacol Ther , vol.145 , pp. 58-66
    • Marais, A.D.1    Kim, J.B.2    Wasserman, S.M.3    Lambert, G.4
  • 2
    • 84906716305 scopus 로고    scopus 로고
    • Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
    • Cuchel M, Bruckert E, Ginsberg HN, et al; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35:2146-2157. doi: 10. 1093/eurheartj/ehu274
    • (2014) Eur Heart J , vol.35 , pp. 2146-2157
    • European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia1    Cuchel, M.2    Bruckert, E.3    Ginsberg, H.N.4
  • 3
    • 81355160365 scopus 로고    scopus 로고
    • Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipidlowering therapy
    • Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, Marais AD. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipidlowering therapy. Circulation. 2011;124:2202-2207. doi: 10. 1161/ CIRCULATIONAHA. 111. 042523
    • (2011) Circulation , vol.124 , pp. 2202-2207
    • Raal, F.J.1    Pilcher, G.J.2    Panz, V.R.3    Van Deventer, H.E.4    Brice, B.C.5    Blom, D.J.6    Marais, A.D.7
  • 4
    • 84961288617 scopus 로고    scopus 로고
    • Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab
    • Lambert G, Chatelais M, Petrides F, Passard M, Thedrez A, Rye KA, Schwahn U, Gusarova V, Blom DJ, Sasiela W, Marais AD. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab. J Am Coll Cardiol. 2014;64:2299-2300. doi: 10. 1016/j. jacc. 2014. 07. 995
    • (2014) J Am Coll Cardiol , vol.64 , pp. 2299-2300
    • Lambert, G.1    Chatelais, M.2    Petrides, F.3    Passard, M.4    Thedrez, A.5    Rye, K.A.6    Schwahn, U.7    Gusarova, V.8    Blom, D.J.9    Sasiela, W.10    Marais, A.D.11
  • 5
    • 84887164358 scopus 로고    scopus 로고
    • Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia
    • Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128:2113-2120. doi: 10. 1161/CIRCULATIONAHA. 113. 004678
    • (2013) Circulation , vol.128 , pp. 2113-2120
    • Stein, E.A.1    Honarpour, N.2    Wasserman, S.M.3    Xu, F.4    Scott, R.5    Raal, F.J.6
  • 6
    • 84921459685 scopus 로고    scopus 로고
    • Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial
    • Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:341-350. doi: 10. 1016/S0140-6736(14)61374-X
    • (2015) Lancet , vol.385 , pp. 341-350
    • Raal, F.J.1    Honarpour, N.2    Blom, D.J.3    Hovingh, G.K.4    Xu, F.5    Scott, R.6    Wasserman, S.M.7    Stein, E.A.8
  • 8
    • 33749487743 scopus 로고    scopus 로고
    • The adaptor protein Dab2 sorts LDL receptors into coated pits independently of AP-2 and ARH
    • Maurer ME, Cooper JA. The adaptor protein Dab2 sorts LDL receptors into coated pits independently of AP-2 and ARH. J Cell Sci. 2006;119(pt 20):4235-4246. doi: 10. 1242/jcs. 03217
    • (2006) J Cell Sci , vol.119 , pp. 4235-4246
    • Maurer, M.E.1    Cooper, J.A.2
  • 9
    • 0036897341 scopus 로고    scopus 로고
    • Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1
    • Eden ER, Patel DD, Sun XM, Burden JJ, Themis M, Edwards M, Lee P, Neuwirth C, Naoumova RP, Soutar AK. Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1. J Clin Invest. 2002;110:1695-1702. doi: 10. 1172/JCI16445
    • (2002) J Clin Invest , vol.110 , pp. 1695-1702
    • Eden, E.R.1    Patel, D.D.2    Sun, X.M.3    Burden, J.J.4    Themis, M.5    Edwards, M.6    Lee, P.7    Neuwirth, C.8    Naoumova, R.P.9    Soutar, A.K.10
  • 12
    • 84902096056 scopus 로고    scopus 로고
    • Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects
    • Lambert G, Petrides F, Chatelais M, Blom DJ, Choque B, Tabet F, Wong G, Rye KA, Hooper AJ, Burnett JR, Barter PJ, Marais AD. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. J Am Coll Cardiol. 2014;63:2365-2373. doi: 10. 1016/j. jacc. 2014. 02. 538
    • (2014) J Am Coll Cardiol , vol.63 , pp. 2365-2373
    • Lambert, G.1    Petrides, F.2    Chatelais, M.3    Blom, D.J.4    Choque, B.5    Tabet, F.6    Wong, G.7    Rye, K.A.8    Hooper, A.J.9    Burnett, J.R.10    Barter, P.J.11    Marais, A.D.12
  • 13
    • 60749122013 scopus 로고    scopus 로고
    • Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells
    • Fasano T, Sun XM, Patel DD, Soutar AK. Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. Atherosclerosis. 2009;203:166-171. doi: 10. 1016/j. atherosclerosis. 2008. 10. 027
    • (2009) Atherosclerosis , vol.203 , pp. 166-171
    • Fasano, T.1    Sun, X.M.2    Patel, D.D.3    Soutar, A.K.4
  • 14
    • 84952939391 scopus 로고    scopus 로고
    • Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort
    • Averna M, Cefalù AB, Stefanutti C, Di Giacomo S, Sirtori CR, Vigna G. Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort. Nutr Metab Cardiovasc Dis. 2016;26:36-44. doi: 10. 1016/j. numecd. 2015. 11. 001
    • (2016) Nutr Metab Cardiovasc Dis , vol.26 , pp. 36-44
    • Averna, M.1    Cefalù, A.B.2    Stefanutti, C.3    Di Giacomo, S.4    Sirtori, C.R.5    Vigna, G.6
  • 15
    • 84871945617 scopus 로고    scopus 로고
    • Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study
    • Cuchel M, Meagher EA, du Toit Theron H, et al; Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40-46. doi: 10. 1016/S0140-6736(12)61731-0
    • (2013) Lancet , vol.381 , pp. 40-46
    • Cuchel, M.1    Meagher, E.A.2    Du Toit, T.H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.